nafamostat and penciclovir

nafamostat has been researched along with penciclovir in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ1

Reviews

2 review(s) available for nafamostat and penciclovir

ArticleYear
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22

    Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries

2020
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
    EMBO molecular medicine, 2021, 01-11, Volume: 13, Issue:1

    Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication

2021

Other Studies

1 other study(ies) available for nafamostat and penciclovir

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023